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Abstract
Introduction: The HIV care cascade examines the attrition of people living with HIV from diagnosis to the use of antiretroviral
therapy (ART) and suppression of viral replication. We reviewed the literature from sub-Saharan Africa to assess the defini-
tions used for the different steps in the HIV care cascade.
Methods: We searched PubMed, Embase and CINAHL for articles published from January 2004 to December 2020. Longitu-
dinal and cross-sectional studies were included if they reported on at least one step of the UNAIDS 90-90-90 cascade or two
steps of an extended 7-step cascade. A step was clearly defined if authors reported definitions for numerator and denomina-
tor, including the description of the eligible population and methods of assessment or measurement. The review protocol has
been published and registered in Prospero.
Results and discussion: Overall, 3364 articles were screened, and 82 studies from 19 countries met the inclusion criteria.
Most studies were from Southern (38 studies, 34 from South Africa) and East Africa (29 studies). Fifty-eight studies (71.6%)
were longitudinal, with a median follow-up of three years. The medium number of steps covered out of 7 steps was 3 (in-
terquartile range [IQR] 2 to 4); the median year of publication was 2015 (IQR 2013 to 2019). The number of different defini-
tions for the numerators ranged from four definitions (for step “People living with HIV”) to 21 (step “Viral suppression”). For
the denominators, it ranged from three definitions (“Diagnosed and aware of HIV status”) to 14 (“Viral suppression”). Only 12
studies assessed all three of the 90-90-90 steps. Most studies used longitudinal data, but denominator–denominator or
denominator–numerator linkages over several steps were rare. Also, cascade data are lacking for many countries. Our review
covers the academic literature but did not consider other data, such as government reports on the HIV care cascade. Also, it
did not examine disengagement and reengagement in care.
Conclusions: The proportions of patients retained at each step of the HIV care cascade cannot be compared between studies,
countries and time periods, nor meta-analysed, due to the many different definitions used for numerators and denominators.
There is a need for standardization of methods and definitions.
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1 | INTRODUCTION
The Joint United Nations Programme on HIV/AIDS (UNAIDS)
adopted the 90-90-90 targets in 2014 to track progress
towards ending the HIV epidemic. Targets to be reached by
2020 include that 90% of people living with HIV (PLWH) are
aware of their status, 90% of those diagnosed initiate
antiretroviral therapy (ART) and 90% of those on ART achieve
undetectable viral loads to end the HIV epidemic by 2030 [1].
The HIV care cascade examines the attrition of PLWH from
diagnosis of the infection to starting ART and achieving sup-
pression of viral replication. It is used to monitor HIV pro-
gramme performance and to identify gaps and opportunities for
specific interventions to improve retention and outcomes [2].
The number of studies examining the HIV care cascade has
increased steeply, from no such study before 2011 to over
161 studies in 2020 (based on a PubMed search combining
free-text words “HIV”, “care” and “cascade”). These studies
found that in sub-Saharan Africa and elsewhere, significant
gaps remain. For example in South Africa’s North West
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Province, awareness of HIV status among PLWH remained
similar at around 70% in 2014 and 2016 and was consider-
ably lower in men than in women [3]. Among HIV-positive
individuals presenting for initiation of ART in Dakar, Senegal,
16% were lost to follow-up within one year [4]. However,
studies differ concerning the definitions, methods and calcula-
tions used to construct the care cascade [5-7]. It is, therefore,
difficult to compare published cascade research across regions
and calendar periods.
Only a few studies have evaluated the methods used to
define the HIV care cascade in low- and middle-income coun-
tries or sub-Saharan Africa [2,5-8]. To fill this gap, we per-
formed a systematic review of studies published in the
academic literature from sub-Saharan Africa to assess the dif-
ferent methodological approaches used to define the steps in
the HIV care cascade.
2 | METHODS
We examined guidance on systematic reviews of observational
studies [9,10] when planning this review and report our
review according to the PRISMA statement [11]. The review
protocol has been published [12] and was registered in Pros-
pero (PROSPERO registration number CRD42017055863)
[13].
2.1 | Search strategy and inclusion criteria
We searched PubMed, Embase and CINAHL for articles pub-
lished in English from 1 January 2004 up to 3 December
2020, the date of database search. We used Medical Subject
Headings (MeSH terms) and free-text search. The MeSH
terms for HIV and AIDS, and terms “cascade”, “continuum”,
“linkage to care”, “retention in care” and “ART initiation” were
cross-referenced with terms for 62 African countries. The
detailed search strategy has been published elsewhere [12].
Studies were included if they reported on at least one step of
the 90-90-90 cascade or on at least two steps of the
extended cascade. Pairs of reviewers (AG and FV, CM and
DK) screened titles and abstracts. Two reviewers (CM, DK)
independently screened the full text of potentially eligible
studies using a standardized eligibility checklist. Disagree-
ments were resolved through discussion.
2.2 | Definition of steps
Figure 1 illustrates the populations involved in the cascade
(bubbles) and the numerators and denominators (connectors
linking populations) proposed by WHO and others for cross-
sectional and longitudinal cascades [6,14,15]. Seven popula-
tions (steps) are involved: (i) PLWH (diagnosed or undiag-
nosed); (ii) PLWH who have been diagnosed with HIV
infection (the first 90); (iii) PLWH who have been diagnosed
and linked to care; (iv) PLWH who have been diagnosed and
who are retained in pre-ART care; (v) PLWH who have been
diagnosed and started ART; (vi) PLWH who have been diag-
nosed and are retained on ART (the second 90); (vii) PLWH
who have been diagnosed, are retained on ART and are viro-
logically suppressed (the third 90). A study reported on a step
if it provided the number of patients in the numerator and
denominator or a percentage of patients completing the step.
We considered the step as clearly defined if the authors
reported definitions for the numerator and denominator, such
as the description of the population studied and methods of
assessment or measurement.
2.3 | Data extraction
We developed a standardized data extraction sheet, which
was piloted by four reviewers (AG, CM, DK and ME) and
revised. Data extraction was performed independently in
pairs by three reviewers (CM, DK, Leona Hulbert), with dis-
agreement resolved by discussion. Data were then entered
into an EpiData database [16]. We classified study design
into cross-sectional studies, longitudinal studies and studies
that combine both designs (mixed design). We defined
regions of sub-Saharan Africa according to the classification
used by the International epidemiological Databases to Eval-
uate AIDS (IeDEA) [17].
2.4 | Statistical analysis
Descriptive statistical analyses were performed using STATA
version 14.0 (Stata Corporation, College Station, TX, USA) [18].
3 | RESULTS
3.1 | Selection of eligible studies
Overall, 3810 articles were identified (Figure 2). After
removal of duplicates, 3364 articles were screened by title
and abstract, of which 412 were considered potentially eligi-
ble and underwent full-text screening. Five studies reported
on data from the Kenya AIDS Indicator Survey 2012 (KAIS)
[19]. To avoid double-counting of data from the KAIS, we
included the publication reporting on the largest number of
steps in the cascade [20]. A total of 82 studies met the inclu-
sion criteria.
3.2 | Study characteristics
The median year of publication of studies was 2015 (Table 1).
The studies included a median of 1776 people; the largest
study had 884,328 people and the smallest 112 people. Most
studies (58 studies, 71.6%) were longitudinal, with a median
follow-up of three years. The medium number of steps cov-
ered by each study was 3 (interquartile range [IQR] 2 to 4);
12 studies assessed all three of the 90-90-90 steps [8,20-30].
Most studies were from Southern Africa (38 studies, 34 from
South Africa) and East Africa (29 studies). Nineteen countries
were represented (Burkina Faso, Cameroon, Côte d’Ivoire,
Ethiopia, Gabon, Kenya, Lesotho, Malawi, Mozambique, Nige-
ria, Rwanda, Senegal, Sierra Leone, South Africa, Tanzania,
Togo, Uganda, Zambia and Zimbabwe).
3.3 | Data collection and management
In 61 (74.4%) of the studies, data collection was performed
by the clinic or hospital where participants were in care. Sixty-
one (74.4%) studies used data collected through routine clini-
cal records, 35 (42.7%) used questionnaires and 33 (40.2%)
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studies collected samples specifically for the study. Twenty-
eight studies (45.9%) reported using data captured in an elec-
tronic database only, and most of the studies (56, 68.3%) had
a personal identifier assigned to study participants, which
allowed for tracking of the participants along the cascade
(Table 1).
Figure 1. Cascade steps and denominators used for each step. The figure shows the denominators and numerators and their connection
adapted from the WHO framework for cross-sectional and longitudinal studies. *Steps of the 90-90-90 cascade. VS, viral suppression.
Figure 2. Flowchart of study selection.
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3.4 | Number of definitions of numerator and
denominator
The number of different definitions used in the 82 studies for
the numerators defining the different steps ranged from four
definitions (for step “People living with HIV”) to 21 (step “Viral
suppression”). Similarly, the number of different denominators
ranged from three (step “Diagnosed and aware of HIV status”)
to 14 (step “Viral suppression”) (Table 2). The median number
of definitions used across the seven steps was 8 for the
numerator and 8 for the denominator.
3.5 | Numerators and denominators along the
cascade
The most frequently studied cascade populations were PLWH
on ART with viral suppression (the third 90), followed by
PLWH who have been diagnosed and are retained on ART
(the second 90) and PLWH who have been diagnosed and
started ART (Figure 3). In cross-sectional studies, PLWH who
had been diagnosed with HIV infection was the most common
denominator used to describe retention at a subsequent step.
The number of patients retained on ART was another com-
monly used denominator for viral suppression.
As expected, in longitudinal studies, it was common to use
the previous steps as the denominator for the subsequent
step (Figure 3). For example the proportion of PLWH on ART
with suppression of HIV replication was based on the number
who were retained on ART. The latter, in turn, was based on
the number of PLWH starting ART and so forth. In recent
years (2018 to 2020) the denominator used for the step
“Start of ART” changed, with more studies using “Diagnosed
with HIV,” rather than “Retained in care” (Figure S1).
3.6 | Individual steps of the cascade
3.6.1 | People living with HIV
Fifteen studies reported numbers or percentages of PLWH
[8,22-24,26-29,31-36]: 10 were cross-sectional, three were
cohort studies and two of mixed design. All but one reported
on the setting in which the testing took place (Table 2) and
used the number who tested HIV positive as their definition of
the numerator. One study included self-reported HIV status
among people who declined testing. Denominators were also
consistent, with all studies using the number of people tested
for HIV (Figure 3). Target populations tested differed between
studies, ranging from adult residents of a high prevalence com-
munity to a random sample of the general population (Table 2).
3.6.2 | Diagnosed and aware of HIV infection
Twenty-four [20-24,26-31,33-35,37-46] studies reported on
people diagnosed with HIV and aware of their status, with 19
providing definitions for the denominator and numerator. Ten
were cross-sectional, 10 longitudinal and 4 included longitudi-
nal and cross-sectional components (mixed design). Awareness
of HIV infection either relied on self-reported information
(questionnaires or interviews) or was assessed through clinical
records; four studies did not specify the source of information.
In most studies, denominators included the PLWH testing pos-
itive for HIV, but people attending HIV testing or the whole
population were also used (Table 2). Only for eight studies,
HIV diagnosis was the starting point of the cascade.
3.6.3 | Linkage to pre-ART care
Twenty-eight studies reported on this step [20,23,24,26-
28,31,33-35,37-39,41,44,45,47-58]: 15 cohort studies, 10 cross-
sectional and three of mixed design. Twenty-four studies (86%)
provided a clear definition of the step (Table 2). Numerators
were based on self-reported clinic visits or assessments of eligi-
bility for ART, or clinical records, with studies assessing linkage
from 1 to 12 months since diagnosis (Table 2). Denominators
were homogenous, defined as patients newly diagnosed with
HIV or patients testing HIV positive (Figure 3).
3.6.4 | Retention in pre-ART care
Nineteen studies reported on retention in pre-ART care
[2,20,26,27,34,49-51,53-56,59-65], with 12 defining numerators
Table 1. Characteristics of 82 published studies reporting on
the HIV care cascade in sub-Saharan Africa
Characteristic
Year of publication 2015 (2013 to 2019)
No. of people included 1776 (559 to 7536)
Study design
Longitudinal study 58 (71.6%)
Cross-sectional study 18 (22.2%)
Mixed designa 5 (6.25)
No. of steps covered 3 (2 to 4)
Duration of follow-up (years)b 3 (2 to 6)
Total no. of countries included 19
Region
Central Africa 4 (4,9%)
East Africa 29 (35.4%)
Southern Africa 38 (46.3%)
West Africa 7 (8.5%)
Multi-regional study 4 (4.9%)
No. of sitesc 2 (1 to 15)
No. of studies at national level 2 (2.4%)
Data collection methods





Clinical records extracted fromd
Paper files only 6 (9.8%)
Paper and electronic files 10 (16.4%)
Electronic files only 28 (45.9%)
Not reported 17 (27.8%)
Median (interquartile range) or number (%) are shown.
aStudies combining cross-sectional and longitudinal datasets; bdata for
the 58 longitudinal studies; cstudies not reporting on national level or
mobile testing (N = 52); d61 studies where clinical records were used.
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and denominators. Six studies were cross-sectional and 13 lon-
gitudinal. The definitions for numerators differed for the type
of information used (self-reported clinical visit or eligibility
assessment, or clinical records) and the time of assessing reten-
tion after HIV diagnosis. Denominators were heterogeneous
and included people newly diagnosed with HIV, PLWH who
were not eligible for ART or not receiving ART, participants
who present for at least one follow-up visit or people receiving
same-day HIV testing (Table 2).
3.6.5 | Initiation of ART
Thirty-nine studies reported on initiation of ART
[2,21,23,28,33,34,37,40-42,44-47,49-54,23,55-62,64,66,67-75],
with 25 (64%) defining numerators and denominators. Thirty-
two were longitudinal, four of mixed design and three were
cross-sectional. Initiation of ART was either self-reported or
ascertained through clinical records. Most studies used partici-
pants eligible for ART based on CD4 cell count or clinical
staging as the denominator. Three studies used all PLWH as
the denominator (Table 2). The denominator and numerator
also differed regarding the time point at which initiation of
ART was assessed (certain time point since eligibility for ART;
times since diagnosis and number of initiations at the end of
the study period) (Table 2).
3.6.6 | Retention on ART
Overall 46 studies [2,20-24,26-30,32,40,43,45,49-51,53,61,63,
65,68,69,72,74-94] reported on retention on ART or being on
ART and 34 (74%) provided clear definitions of numerators
and denominators. The majority of studies were longitudinal
(29 studies, 63%), 13 were cross-sectional and four of mixed
design. Studies not reporting a clear definition described this
step as "currently on ART" or similar. Numerators were either
self-reported or ascertained through clinical records, phar-
macy records or pill counts (Table 2). Time points for assess-
ing numerators ranged from retention for six months to
ten years of ART. The most frequently used denominator
was based on the patients starting ART (26 studies, 56%)
(Figure 3).
3.6.7 | Viral suppression
A total of 52 studies reported numbers or percentages of
patients retained at this step [8,20-32,34,36,40-
43,46,56,58,65,68,69,72-74,76-93,95-99]. The majority of
studies (32 studies, 62%) covering this step were longitudinal
studies. Viral suppression was based on laboratory results;
one of the studies used self-reported viral suppression as the
definition for the numerator. Variable definitions of viral sup-
pression and time points when viral load was measured led to
different denominators. Thresholds used for definition of viral
suppression ranged from <25 to <5000 copies/mL. The
threshold most frequently used was <400 copies/mL (15 stud-
ies, 31%) (Table 2). Time points at which viral suppression was
assessed ranged from one month to ten years on ART and
was not specified in 18 (35%) out of the 52 studies. The most
frequent time point for the assessment of viral suppression
was 12 months after ART initiation (15 studies, 31%). The
Figure 3. Cascade steps and denominators used for each step in 82 studies. Bubbles represent numerators, connectors point to the corre-
sponding denominator.
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denominators used varied widely. It ranged from all PLWH
patients to patients with available viral load (VL) measurement
at 10 years (Table 2).
4 | DISCUSSION
This systematic review of published studies from sub-Saharan
Africa examined the approaches used to define the steps in
the HIV care cascade and the steps covered in studies. Its
results show that the definitions of the steps along the HIV
care cascade are highly heterogeneous. Only 12 studies
assessed all three 90-90-90 steps. Many studies focused on a
subset of steps, with most studies assessing the start of ART,
retention on ART, and achieving viral suppression. These steps
are easier to assess within a typical clinic-based cohort and
are also part of the 90-90-90 goals proposed by UNAIDS,
which might explain the numerous studies reporting on these
steps. Fewer studies examined the earlier steps, including the
proportion of PLWH who have been diagnosed with HIV
infection (the first 90) or the step of linkage to care.
The various definitions used for numerators and denomina-
tors mean that the proportions of patients retained at each
step cannot easily be compared between studies, countries
and time periods. Also, the statistical combination of data in
meta-analyses, for example, for one country or region, would
be problematic in this situation because "apples are combined
with oranges" [100]. The heterogeneous definitions may be
explained by the focus of studies, which may have been on
retention in general, not specifically on the 90-90-90 targets.
Of note, for the step of viral suppression, where definitions
could be expected to be more consistent than for other steps,
we identified a total of 21 different numerator definitions.
Changing viral load thresholds over time and different time-
points of measuring contributed to the many different numer-
ators, reflecting changing recommendations for defining viral
suppression. The denominators also varied widely, ranging
from all PLWH to patients starting ART. In recent years,
PLWH diagnosed with HIV became a more common denomi-
nator for the proportion of patients on ART, reflecting the
introduction of the “treat-all” guidelines. “Retention in pre-
ART” care does no longer apply with “treat-all”.
Previous studies from high-income and lower-income set-
tings have highlighted the lack of uniformity in definitions [5-
7,101,102]. To the best of our knowledge, this is the first
comprehensive review of the methods used to assess the full
HIV care cascade in sub-Saharan Africa, including the defini-
tions of numerators and denominators from cross-sectional
and longitudinal studies. Most previous studies focused on
one part of the HIV care cascade, for example highlighting the
lack of uniformity following specific community-based testing
strategies [103,104], or on other settings, for example high-
income countries [7,105]. Several studies from high-income
settings have previously highlighted the heterogeneity and
lack of standardization [101,102]. Haber and colleagues rec-
ommended investments in population-based, longitudinal
cohorts so that data can be linked at the individual level
across steps (denominator–denominator linkage) and within
steps (denominator–numerator linkage) [6]. We found that the
majority of studies reporting on the cascade use longitudinal
rather than cross-sectional data. However, denominator–
denominator or denominator–numerator linkages over several
steps were rare. Globally agreed-upon measures to quantify
the HIV care cascade are needed to evaluate the scope of
and factors that are associated with attrition along the cas-
cade [6,14,105,106].
A strength of our study is that we included smaller surveys
and cohorts that are not necessarily representative of the
national level but highly relevant to many settings in sub-
Saharan Africa. Some weaknesses need to be considered. Our
review was based on a systematic search of the academic liter-
ature and did not consider other reports on the HIV care cas-
cade. For example we did not include reports published by
governments describing national care continua. Of note, a sys-
tematic review of national data found that only a few complete
national continua of care were available, and there was much
heterogeneity in the methods for determining progress towards
the 90-90-90 target [5]. A previous systematic review identified
13 cascades from the USA, Canada, Denmark, Georgia and
Australia and recommended the use of population-based data
sets to improve comparability [7]. Another study examined the
linkage steps to care and ART initiation following community-
based detection of HIV [107]. Similar to our research, the
authors found that definitions of numerators and denominators
and observation periods were heterogeneous and that a meta-
analysis was inappropriate. We did not examine disengagement
and reengagement in care. Such “churning in and out of HIV
care” was beyond the scope of this review [108].
We did not systematically search for reports from the
Population-based HIV Impact Assessment (PHIA) surveys and
did not include them [109,110]. The PHIA project performed
nationally representative cross-sectional surveys for 13 differ-
ent countries, measuring the three 90-90-90 steps of the HIV
care cascade. In contrast to the academic literature, multina-
tional studies, which use a standardized methodology, can pro-
vide data that are comparable across countries. Where a
population-based nationwide cohort is missing, combined
information from cross-sectional studies, cohort studies and
from health surveillance is often used to evaluate the HIV cas-
cade of care. A weakness that applies both to the PHIA sur-
veys and the academic literature is the limited coverage of
data on the care cascade. In our review, we identified studies
from 19 countries in sub-Saharan Africa. Therefore, data on
the care cascade may still be lacking for some countries,
including countries profoundly affected by the HIV epidemic.
The IeDEA collaboration is an extensive network of clinical
cohorts, which can address the later steps of the HIV cascade
in a standardized way [17,111].
5 | CONCLUSIONS
In conclusion, the many different numerators and denomina-
tors used along the HIV care cascade limit the comparability
between studies. It is not clear whether observed differences
in results are due to real differences or different approaches
to the calculation of numerators and denominators. Future
studies assessing the HIV care cascade should provide clear
definitions of numerators and denominators used. To identify
gaps and opportunities for specific interventions to improve
the cascade of care, we need standard definitions, such as
those definitions proposed by the WHO [14].
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Figure S1. Cascade steps and denominators used for each
step. Bubbles represent numerators; connectors point to the
corresponding denominator. Original search (upper panel) and
new studies (lower panel).
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